Cyclosporin A (CAS 59865-13-3) is a cyclic polypeptide immunosuppressant composed of 11 amino acids, originally isolated from the fungus Tolypocladium inflatum. It revolutionised transplant medicine thanks to its ability to selectively inhibit T-lymphocyte activation, dramatically reducing organ rejection rates and enabling long-term graft survival.
The TCS INDUSTRIES LIMITED product
Cyclosporin A 59865-13-3 | Immunomodulator Pharmaceutical API Factory China
is presented as a high-purity API intended for formulations used in solid organ transplantation, rheumatoid arthritis, psoriasis, nephrotic syndrome and other autoimmune indications. The compound is practically insoluble in water but soluble in various organic solvents, which has led to the development of specific oral solution and capsule technologies, as well as injectable emulsions.
Within the TCS GROUP portfolio, Cyclosporin A belongs to the core
Active Pharmaceutical Ingredient
category. Its immunomodulatory profile places it alongside other advanced APIs and intermediates aimed at chronic, high-value therapeutic areas. For companies focused on ophthalmology or neurology, related cholinergic/anticholinesterase materials such as
can complement cyclosporin-based portfolios, particularly when covering glaucoma or complex ocular-immune interfaces.
Cyclosporin A’s mechanism is based on complex formation with cyclophilin, followed by inhibition of calcineurin, leading to reduced transcription of interleukin-2 and other cytokines necessary for full T-cell activation. Because of its narrow therapeutic index and potential nephrotoxicity, careful therapeutic drug monitoring, controlled release and consistent bioavailability are essential.
TCS INDUSTRIES LIMITED leverages its experience in complex APIs and intermediates to support partners across product life cycles—from early development to mature generic products. For advanced process work or novel analogs, customers may also draw on the
portfolio, allowing integrated sourcing strategies for cyclosporin derivatives and other immunomodulatory chemistries.
By partnering with TCS GROUP for Cyclosporin A 59865-13-3, manufacturers gain a robust foundation for transplant and autoimmune therapies, backed by stringent quality systems, documentation support and a wider ecosystem of complementary APIs and intermediates.